Last updated: April 23, 2026
Who Supplies Norgestrel APIs and Finished Dosage Forms?
What companies supply norgestrel (API) for pharmaceutical use?
Norgestrel is supplied through both API manufacturers and contract development and manufacturing organizations (CDMOs) that produce norgestrel-containing hormonal products. The global supply chain is concentrated in China and India for API and in multi-country CDMO networks for tablet and capsule dosage forms, with several firms positioned across both API and finished dosage manufacturing.
API and intermediates supply (common market sources)
The following supplier classes are used in practice for norgestrel API and related steroid intermediates:
- Steroid-intermediate and hormone API manufacturers (typically supply norgestrel substance directly or via standard steroid intermediate routes)
- Specialty hormone API makers (niche manufacturers focused on contraceptive and reproductive health actives)
- CDMO partners that procure the API and manufacture finished dosage form under GMP
Practical supplier short-list used by buyers
- China-based steroid/hormone API manufacturers with US/EU documentation capability
- India-based API manufacturers with EU/US filing support for hormonal APIs
- European/US CDMOs that support formulation, tablet/capsule manufacturing, and packaging for contraceptive products using either internally sourced or customer-supplied API
Which finished-dose suppliers make norgestrel products?
Norgestrel appears in marketed oral contraceptives and progestin-based regimens. Finished-dose supply typically comes from:
- Originator or legacy brand manufacturers in regional markets
- Generic manufacturers with ANDA/MAA submissions in target jurisdictions
- CDMOs producing tablets packaged under marketing authorization holders
Because norgestrel is a progestin used in combination products (with ethinylestradiol or other estrogens) and also in progestin-only contexts depending on country, finished-dose supply is often tied to specific authorization holders and local labeling formats, not only to the API source.
Where does norgestrel supply originate geographically?
Global supply for norgestrel generally concentrates in:
- Asia (API and intermediate production): China and India dominate volume and cost competitiveness for steroid actives.
- Europe and North America (finished dosage and controlled manufacturing networks): often via CDMO or contract manufacturing for EU/US packaging standards.
How do buyers typically qualify norgestrel suppliers?
For norgestrel, qualification is driven by regulatory and quality documentation needs:
- GMP compliance for API manufacturing (and for finished dose if the supplier also manufactures)
- DMF/CEP alignment for target regulatory jurisdictions
- Analytical package completeness: CoA, impurity profile, residual solvents, polymorph/solid-state controls (as applicable)
- Supply continuity: sourcing resilience for steroid intermediates that feed the norgestrel route
What documentation is typically required from norgestrel suppliers?
In sourcing packages, buyers generally expect:
- Certificate of Analysis (CoA) for each lot
- Specification sheet (identity, assay, impurities, water content, residual solvents)
- Impurity and impurity control strategy mapped to the route and regulatory expectations
- GMP inspection evidence (inspection history or equivalent compliance documentation)
What are the main supplier archetypes in the norgestrel chain?
- API manufacturers producing norgestrel substance under GMP
- Steroid intermediate manufacturers upstream that sell intermediates used to make norgestrel
- CDMOs / manufacturers of tablets and packaged products using supplied API
What should procurement teams verify before selecting a norgestrel supplier?
- Regulatory readiness: ability to support EU/US filings through DMF or equivalent dossiers
- Quality consistency: validated impurity controls and stable specs over time
- Technical transfer support if moving from existing supplier: analytical alignment and manufacturing comparability
Key Takeaways
- Norgestrel supply comes through API manufacturers and CDMOs, with Asia-based firms dominating API and intermediate production.
- Finished dosage supply is typically routed through local generic/brand manufacturers or CDMOs that produce tablets for specific market authorizations.
- Supplier qualification hinges on GMP compliance, dossier support (DMF/CEP equivalents), and complete analytical documentation.
FAQs
1) Is norgestrel usually sourced as an API or within finished dosage?
Most supply is structured as API procurement by marketing authorization holders or CDMOs, with finished dosage production handled separately by manufacturers or CDMOs.
2) Which regions dominate norgestrel API supply?
Supply volume is concentrated in China and India, with finished dosage and packaging often executed in Europe and North America via manufacturers and CDMOs.
3) What documentation matters most for norgestrel API suppliers?
Buyers prioritize GMP evidence, CoA per lot, specifications, impurity profiles, and dossier support (DMF/CEP-type alignment).
4) Do norgestrel suppliers overlap with broader progestin or steroid suppliers?
Yes. Many suppliers that handle steroid intermediates and progestins also supply related hormonal APIs, since routes and containment/quality systems overlap.
5) Can CDMOs supply norgestrel-containing tablets without owning the API?
Yes. Many CDMOs operate with customer-supplied API or source API through approved channels, then execute formulation and tablet manufacturing under GMP.
References
[1] U.S. Food and Drug Administration (FDA). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
[2] European Medicines Agency (EMA). European public assessment reports and product information for contraceptives and progestins. EMA.
[3] World Health Organization (WHO). WHO Model Quality Assessed Templates and guidance for quality documentation of pharmaceuticals. WHO.
[4] USP and/or Ph. Eur. monographs for hormonal substances and specifications (where applicable to norgestrel-related testing). United States Pharmacopeia / European Pharmacopoeia.
